Efficacy of Modified Thoracoabdominal Nerves Block Through Perichondrial Approach in Total Laparoscopic Hysterectomies

Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06116409
Collaborator
(none)
50
1
2.5
20.3

Study Details

Study Description

Brief Summary

TAPA is a new analgesic block technique that involves the injection of local anesthetics into the thoracoabdominal nerves using a perichondrial approach. Application to the undersurface of the rib cartilage is considered as Modified TAPA (M-TAPA). These techniques are commonly applied for postoperative analgesia in surgeries and are effective and safe when performed under ultrasound guidance.

Condition or Disease Intervention/Treatment Phase

Detailed Description

Between September 2023 and October 2023, a study will be conducted involving 50 elective total laparoscopic hysterectomy patients aged 18-65 with ASA (American Society of Anesthesiologists) physical status classification of 1-3. Patients with ASA status 4 or higher, aged 65 and above, under 18 years of age, those who have previously undergone laparotomy, or those with a known local anesthesia allergy will not be included in the study. Patients who require intubation and are admitted to the intensive care unit, or those who experience mortality, will be excluded from the study.

One day before surgery, all patients will undergo a preoperative assessment and provide written informed consent to participate in the study. Patients will be randomly assigned to groups using a computer-generated random table. In Group 1, patients will receive a modified thoracoabdominal nerve block (M-TAPA) with a perichondrial approach using 40 ml of 0.25% bupivacaine guided by ultrasound (US). In Group 2 (the control group), routine multimodal analgesia (tramadol 1 mg/kg, paracetamol 15 mg/kg) will be administered. The needle-like spread of bupivacaine or saline beneath the undersurface of the rib cartilage, observed under US, will indicate the success of the procedure. These procedures will be performed postoperatively. At the end of the surgery, both groups will receive 1 mg/kg tramadol IV and 15 mg/kg paracetamol IV for analgesia.

Demographic data, medical history, ASA classification, and the presence of coronary artery disease (CAD) and overactive bladder (OAB) before and after M-TAPA, anesthesia time, surgical duration, time to tracheal extubation (time after skin closure), total remifentanil and muscle relaxant doses, total fluid administered, urine volume, and the total volume of allogeneic erythrocytes and plasma infused during the surgery will be recorded. Additionally, postoperative hypotension development (systolic blood pressure dropped more than 30% from baseline or SBP < 80 mmHg before anesthesia), nausea and vomiting, hypoxemia (SpO2 < 90% or PaO2 < 60 mmHg), hypercapnia (PaCO2 > 45 mmHg), and agitation during the waking period will be recorded.

In the ward, 2*1 non-steroidal anti-inflammatory drugs (NSAIDs) will be administered for analgesia. Numerical Rating Scale (NRS) will be assessed postoperatively at 2, 6, 12, and 24 hours, and tramadol consumption will be recorded. A numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain) will be used for pain assessment. If NRS is greater than 4, rescue analgesia with tramadol will be administered. After surgery, all patients will be transferred to the post-anesthesia care unit (PACU).

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Efficacy of Modified Thoracoabdominal Nerves Block Through Perichondrial Approach in Total Laparoscopic Hysterectomies on Postoperative Pain
Actual Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Nov 15, 2023

Arms and Interventions

Arm Intervention/Treatment
M-TAPA GROUP

Group 1 patients will receive a modified thoracoabdominal nerve block (M-TAPA) with a perichondrial approach using 40 ml of 0.25% bupivacaine guided by ultrasound (US).

Drug: Bupivacain
Bupivacaine was used for postoperative analgesia block.

CONTROL GROUP

Patients in Group 2 (the control group) will receive routine multimodal analgesia, which includes tramadol at a dose of 1 mg/kg and paracetamol at a dose of 15 mg/kg.

Outcome Measures

Primary Outcome Measures

  1. Evaluate patients' postoperative pain [postoperative 24 hours]

    The primary aim of this study is to evaluate and compare the postoperative analgesic effectiveness of modified thoracoabdominal nerve block (M-TAPA) in total laparoscopic hysterectomy. Numerical rating scale (NRS) will be used for postoperative analgesic effectiveness. NRS ranging from 0 (no pain) to 10 (worst imaginable pain) will be used for pain assessment. If NRS is greater than 4, rescue analgesia with tramadol will be administered.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • electively total laparoscopic hysterectomy operations

  • ASA II-III,

  • between 18-65 years

Exclusion Criteria:
  • ASA IV and above • over 65 - under 18 years of age allergy to local anesthetics

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Health Science, Kartal Dr Lütfi Kırdar Training and Research Hospital Istanbul İ̇stanbul Turkey

Sponsors and Collaborators

  • Dr. Lutfi Kirdar Kartal Training and Research Hospital

Investigators

  • Principal Investigator: hülya yılmaz ak, Kartal Dr Lutfi Kırdar City Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
kübra taşkın, specialist medical doktor, Dr. Lutfi Kirdar Kartal Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT06116409
Other Study ID Numbers:
  • DrLutfiKirdarANESTHESİA
First Posted:
Nov 3, 2023
Last Update Posted:
Nov 3, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2023